Greg Zante, Chief Financial Officer at Viking Therapeutics, Inc. (VKTX), sold 77,994 shares at $17.90 ($1.4M) on 2024-01-04, disclosed to the SEC on 2024-01-04.
Seasonal sale ($1.4M) by Chief Financial Officer — this insider has traded VKTX in January in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.40 | 18,233 | $317K | 23.0% |
| 2 | $17.40 | 30,889 | $537K | 38.9% |
| 3 | $17.90 | 15,000 | $269K | 19.4% |
| 4 | $18.58 | 13,872 | $258K | 18.7% |
| Total | $17.71 avg | 77,994 | $1.4M | 100% |
| Filing → |
| VKTX | SELL | 2025-10-28 | $216K | — | Filing → |
| VKTX | SELL | 2025-07-03 | $237K | — | Filing → |
| VKTX | SELL | 2025-01-06 | $4.1M | — | Filing → |